Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

CompletedOBSERVATIONAL
Enrollment

224

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Ankylosing Spondylitis (AS)PsoriasisRheumatoid Arthritis (RA)
Trial Locations (10)

200041

AbbVie China /ID# 164373, Shanghai

310014

Zhejiang Province People's Hospital /ID# 209342, Hangzhou

310018

Sir Run Run Shaw Hospital /ID# 210820, Hangzhou

314000

The First Hospital of Jiaxing /ID# 213686, Jiaxing

314033

The Second Hospital of Jiaxing /ID# 210744, Jiaxing

321000

Jinhua Municipal Central Hospital /ID# 209339, Jinhua

518040

Shenzhen Futian Hospital for rheumatic Diseases /ID# 209340, Shenzhen

610041

Sichuan Provincial orthopedic hospital /ID# 209341, Chengdu

West China Hospital, SCU West China School of Medicine, SCU /ID# 209333, Chengdu

610500

The First affiliated hospital of chengdu medical university /ID# 210745, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY